Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience

Cheng-ying Zhu; Sha-sha Zhao; Xiao-kai Wang; Li Wang; Fei-yan Wang; Shu Fang; Zhan-xiang Liu; Li-xun Guan; Yu-chen Liu; Yi Ding; Li-ping Dou; Li-li Wang; Chun-ji Gao

doi:10.12659/AOT.914101

03 April 2019 : Original article

Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience

Cheng-ying Zhu^{BCDEFG 1,2}, Sha-sha Zhao^{B 2}, Xiao-kai Wang^{BCE 3}, Li Wang^{BC 4}, Fei-yan Wang^{CD 1}, Shu Fang^{EF 2}, Zhan-xiang Liu^{B 2}, Li-xun Guan^{D 2}, Yu-chen Liu^{D 2}, Yi Ding^{E 2}, Li-ping Dou^{D 2}, Li-li Wang^{D 2}, Chun-ji Gao^{FG 1,2*}

DOI: 10.12659/AOT.914101

Ann Transplant 2019; 24:175-184

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Back to the Article

Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience

Your Privacy